Kiniksa expects 2024 ARCALYST net product revenue of between $405 million and $415 million, compared to prior guidance of between $370 million and $390 million. Kiniksa expects to remain cash flow positive on an annual basis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
- Kiniksa commence enrollment in Phase 2b trial of abiprubart
- Kiniksa files $400M mixed securities shelf
- Kiniksa, NHL Hall-of-Famer Henrik Lundqvist partner for pericarditis awareness
- Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis
Questions or Comments about the article? Write to editor@tipranks.com